Cover Image
Market Research Report

Cardiac Resynchronisation Therapy (CRT) - Medical Devices Pipeline Assessment, 2019

Published by GlobalData Product code 358888
Published Content info 90 Pages
Delivery time: 1-2 business days
Price
Back to Top
Cardiac Resynchronisation Therapy (CRT) - Medical Devices Pipeline Assessment, 2019
Published: December 17, 2019 Content info: 90 Pages
Description

GlobalData's Medical Devices sector report, "Cardiac Resynchronisation Therapy (CRT) - Medical Devices Pipeline Assessment, 2019" provides an overview of Cardiac Resynchronisation Therapy (CRT) currently in pipeline stage.

The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Cardiac Resynchronisation Therapy (CRT) pipeline products.

This report is prepared using data sourced from in-house databases, secondary and primary research by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.

Scope

  • Extensive coverage of the Cardiac Resynchronisation Therapy (CRT) under development
  • The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
  • The report reviews the major players involved in the development of Cardiac Resynchronisation Therapy (CRT) and list all their pipeline projects
  • The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage
  • The report provides key clinical trial data of ongoing trials specific to pipeline products
  • Recent developments in the segment / industry

Reasons to buy

The report enables you to -

  • Formulate significant competitor information, analysis, and insights to improve R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of Cardiac Resynchronisation Therapy (CRT) under development
  • Develop market-entry and market expansion strategies
  • Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
  • In-depth analysis of the product's current stage of development, territory and estimated launch date
Table of Contents
Product Code: GDME0868EPD

Table of Contents

  • 1.1 List of Tables 4
  • 1.2 List of Figures 5

2 Introduction 6

  • 2.1 Cardiac Resynchronisation Therapy (CRT) Overview 6

3 Products under Development 7

  • 3.1 Cardiac Resynchronisation Therapy (CRT) - Pipeline Products by Stage of Development 7
  • 3.2 Cardiac Resynchronisation Therapy (CRT) - Pipeline Products by Segment 8
  • 3.3 Cardiac Resynchronisation Therapy (CRT) - Pipeline Products by Territory 9
  • 3.4 Cardiac Resynchronisation Therapy (CRT) - Pipeline Products by Regulatory Path 10
  • 3.5 Cardiac Resynchronisation Therapy (CRT) - Pipeline Products by Estimated Approval Date 11
  • 3.6 Cardiac Resynchronisation Therapy (CRT) - Ongoing Clinical Trials 12

4 Cardiac Resynchronisation Therapy (CRT) - Pipeline Products under Development by Companies 13

  • 4.1 Cardiac Resynchronisation Therapy (CRT) Companies - Pipeline Products by Stage of Development 13
  • 4.2 Cardiac Resynchronisation Therapy (CRT) - Pipeline Products by Stage of Development 14

5 Cardiac Resynchronisation Therapy (CRT) Companies and Product Overview 15

  • 5.1 Boston Scientific Corp Company Overview 15
    • 5.1.1 Boston Scientific Corp Pipeline Products & Ongoing Clinical Trials Overview 15
  • 5.2 DHS Medical Company Overview 20
    • 5.2.1 DHS Medical Pipeline Products & Ongoing Clinical Trials Overview 20
  • 5.3 EBR Systems Inc Company Overview 22
    • 5.3.1 EBR Systems Inc Pipeline Products & Ongoing Clinical Trials Overview 22
  • 5.4 IRadimed Corp Company Overview 26
    • 5.4.1 IRadimed Corp Pipeline Products & Ongoing Clinical Trials Overview 26
  • 5.5 Johns Hopkins University Company Overview 27
    • 5.5.1 Johns Hopkins University Pipeline Products & Ongoing Clinical Trials Overview 27
  • 5.6 Mayo Clinic Company Overview 28
    • 5.6.1 Mayo Clinic Pipeline Products & Ongoing Clinical Trials Overview 28
  • 5.7 Medtronic plc Company Overview 29
    • 5.7.1 Medtronic plc Pipeline Products & Ongoing Clinical Trials Overview 29
  • 5.8 MicroPort CRM Company Overview 31
    • 5.8.1 MicroPort CRM Pipeline Products & Ongoing Clinical Trials Overview 31
  • 5.9 NewPace Ltd Company Overview 33
    • 5.9.1 NewPace Ltd Pipeline Products & Ongoing Clinical Trials Overview 33
  • 5.10 Odem Medical Ltd Company Overview 34
    • 5.10.1 Odem Medical Ltd Pipeline Products & Ongoing Clinical Trials Overview 34

6 Cardiac Resynchronisation Therapy (CRT)- Recent Developments 35

  • 6.1 Nov 19, 2019: Medtronic reports second quarter financial results for the year 2019 35
  • 6.2 Nov 14, 2019: Medtronic highlights leadership in inclusion, diversity, and equity in 2019 integrated performance report 37
  • 6.3 Oct 30, 2019: LivaNova reports third quarter 2019 results 38
  • 6.4 Oct 23, 2019: Boston Scientific announces results for third quarter 2019 39
  • 6.5 Oct 21, 2019: Sean Salmon named executive vice president and group president of Medtronic Diabetes 41

7 Appendix 87

  • 7.1 Methodology 87
  • 7.2 About GlobalData 90
  • 7.3 Contact Us 90
  • 7.4 Disclaimer 90

List of Tables

  • Table 1: Cardiac Resynchronisation Therapy (CRT) - Pipeline Products by Stage of Development
  • Table 2: Cardiac Resynchronisation Therapy (CRT) - Pipeline Products by Segment
  • Table 3: Cardiac Resynchronisation Therapy (CRT) - Pipeline Products by Territory
  • Table 4: Cardiac Resynchronisation Therapy (CRT) - Pipeline Products by Regulatory Path
  • Table 5: Cardiac Resynchronisation Therapy (CRT) - Pipeline Products by Estimated Approval Date
  • Table 6: Cardiac Resynchronisation Therapy (CRT) - Ongoing Clinical Trials
  • Table 7: Cardiac Resynchronisation Therapy (CRT) Companies - Pipeline Products by Stage of Development
  • Table 8: Cardiac Resynchronisation Therapy (CRT) - Pipeline Products by Stage of Development
  • Table 9: Boston Scientific Corp Pipeline Products & Ongoing Clinical Trials Overview
  • Table 10: Next Generation Quad Polar CRT-D - Product Status
  • Table 11: Next Generation Quad Polar CRT-D - Product Description
  • Table 12: NG3 Non Quad System - Product Status
  • Table 13: NG3 Non Quad System - Product Description
  • Table 14: Resonate 2.0 - Product Status
  • Table 15: Resonate 2.0 - Product Description
  • Table 16: Boston Scientific Corp - Ongoing Clinical Trials Overview
  • Table 17: Next Generation Quad Polar CRT-D - Heart Failure Indication and Sudden Cardiac Death Prevention Trial Japan
  • Table 18: DHS Medical Pipeline Products & Ongoing Clinical Trials Overview
  • Table 19: Drimmer - Product Status
  • Table 20: Drimmer - Product Description
  • Table 21: Twistek - Product Status
  • Table 22: Twistek - Product Description
  • Table 23: EBR Systems Inc Pipeline Products & Ongoing Clinical Trials Overview
  • Table 24: Second Generation WiSE CRT System - Product Status
  • Table 25: Second Generation WiSE CRT System - Product Description
  • Table 26: WiSE CRT System - Product Status
  • Table 27: WiSE CRT System - Product Description
  • Table 28: EBR Systems Inc - Ongoing Clinical Trials Overview
  • Table 29: WiSE CRT System - Image Optimization and Guidance for Wireless Endocardial Cardiac Resynchronization Therapy: The CT Guided Trial
  • Table 30: WiSE CRT System - Multicenter, Prospective Evaluation of Safety and Performance of the WiCS-LV System in Patients Indicated for Cardiac Resynchronization Therapy
  • Table 31: WiSE CRT System - Stimulation of the Left Ventricular Endocardium for Cardiac Resynchronization Therapy in Non-responders and Previously Untreatable Patients (SOLVE CRT)
  • Table 32: IRadimed Corp Pipeline Products & Ongoing Clinical Trials Overview
  • Table 33: MR Defibrillator - Product Status
  • Table 34: MR Defibrillator - Product Description
  • Table 35: Johns Hopkins University Pipeline Products & Ongoing Clinical Trials Overview
  • Table 36: Cardiac Arrhythmia Termination Device - Product Status
  • Table 37: Cardiac Arrhythmia Termination Device - Product Description
  • Table 38: Mayo Clinic Pipeline Products & Ongoing Clinical Trials Overview
  • Table 39: Atrial Fibrillation Device - Product Status
  • Table 40: Atrial Fibrillation Device - Product Description
  • Table 41: Medtronic plc Pipeline Products & Ongoing Clinical Trials Overview
  • Table 42: MRI Safe CRT-D - Product Status
  • Table 43: MRI Safe CRT-D - Product Description
  • Table 44: Next Gen ICD And CRT-D - Product Status
  • Table 45: Next Gen ICD And CRT-D - Product Description
  • Table 46: MicroPort CRM Pipeline Products & Ongoing Clinical Trials Overview
  • Table 47: PARADYM RF SonR CRT-D - Product Status
  • Table 48: PARADYM RF SonR CRT-D - Product Description
  • Table 49: Triple-Site Ventricular (Tri-V) Pacing CRT-D - Product Status
  • Table 50: Triple-Site Ventricular (Tri-V) Pacing CRT-D - Product Description
  • Table 51: NewPace Ltd Pipeline Products & Ongoing Clinical Trials Overview
  • Table 52: The Implantable Subcutaneous String Defibrillator (ISSD) - Product Status
  • Table 53: The Implantable Subcutaneous String Defibrillator (ISSD) - Product Description
  • Table 54: Odem Medical Ltd Pipeline Products & Ongoing Clinical Trials Overview
  • Table 55: Odem Device - Product Status
  • Table 56: Odem Device - Product Description
  • Table 57: Glossary

List of Figures

  • Figure 1: Cardiac Resynchronisation Therapy (CRT) - Pipeline Products by Stage of Development
  • Figure 2: Cardiac Resynchronisation Therapy (CRT) - Pipeline Products by Segment
  • Figure 3: Cardiac Resynchronisation Therapy (CRT) - Pipeline Products by Territory
  • Figure 4: Cardiac Resynchronisation Therapy (CRT) - Pipeline Products by Regulatory Path
  • Figure 5: Cardiac Resynchronisation Therapy (CRT) - Pipeline Products by Estimated Approval Date
  • Figure 6: Cardiac Resynchronisation Therapy (CRT) - Ongoing Clinical Trials
Back to Top